SCHEMBL6410341

SCHEMBL6410341

CC[C@H](C(=O)Cl)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.56
HSD17B10 Q99714 1/20 0.56
KCNQ2 O43526 2/20 0.54
ALDH1A1 P00352 3/20 0.51
POLB P06746 1/20 0.51
CRHBP P24387 2/20 0.50
CRHR2 Q13324 2/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MAPT P10636 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
GAA P10253 2/20 0.49
KDM4A O75164 1/20 0.49
BCHE P06276 1/20 0.49
NPSR1 Q6W5P4 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16820449 1.00 LMNA (0.56) LMNAHSD17B10KCNQ2ALDH1A1POLB
SCHEMBL582647 1.00 LMNA (0.56) LMNAHSD17B10KCNQ2ALDH1A1POLB
SCHEMBL27620277 0.89 PTGS2 (0.50) LMNAHSD17B10KCNQ2ALDH1A1POLB
SCHEMBL4935067 0.85 LMNA (0.61) LMNAHSD17B10KCNQ2ALDH1A1POLB
SCHEMBL20553663 0.84 CTSS (0.49) LMNAHSD17B10KCNQ2ALDH1A1MAPT
SCHEMBL971454 0.84 CYP2C19 (0.48) LMNAHSD17B10KCNQ2ALDH1A1POLB
SCHEMBL8728377 0.84 MAPT (0.45) LMNAHSD17B10KCNQ2ALDH1A1POLB
SCHEMBL1715 0.83 LMNA (0.59) LMNAHSD17B10KCNQ2ALDH1A1POLB
SCHEMBL65737 0.83 LMNA (0.59) LMNAHSD17B10KCNQ2ALDH1A1POLB
SCHEMBL20769804 0.83 LMNA (0.59) LMNAHSD17B10KCNQ2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050154051-A1 Method for the preparation of escitalopram H. LUNDBECK A/S (DK) 2005-07-14 US claimed
EP-1458701-A1 METHOD FOR THE PREPARATION OF ESCITALOPRAM H. Lundbeck A/S (DK) 2004-09-22 EP claimed
WO-2003051861-A1 METHOD FOR THE PREPARATION OF ESCITALOPRAM H. LUNDBECK A/S (DK) 2003-06-26 WO claimed
EP-3676263-B1 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) 2021-10-06 EP disclosed
US-11053230-B2 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. 2021-07-06 US disclosed
EP-3676263-A1 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE Netherlands Translational Research Center B.V. (NL) 2020-07-08 EP disclosed
US-20200181128-A1 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) 2020-06-11 US disclosed
EP-3426638-B1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) 2020-05-06 EP disclosed
WO-2019043103-A1 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) 2019-03-07 WO disclosed
US-20190055213-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) 2019-02-21 US disclosed
EP-3426638-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE Netherlands Translational Research Center B.V. (NL) 2019-01-16 EP disclosed
CN-109071457-A Inhibitors of indoleamine 2, 3-dioxygenase 荷兰转化研究中心有限责任公司 2018-12-21 CN disclosed
WO-2017153459-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) 2017-09-14 WO disclosed
US-20050154051-A1 Method for the preparation of escitalopram H. LUNDBECK A/S (DK) 2005-07-14 US disclosed
EP-1458701-A1 METHOD FOR THE PREPARATION OF ESCITALOPRAM H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051861-A1 METHOD FOR THE PREPARATION OF ESCITALOPRAM H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190055213-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, TPH2 LMNA 4805/4885HSD17B10 538/4885KCNQ2 2374/4885
US-11053230-B2 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase IDO1, IDO2, TPH1 LMNA 4834/4885HSD17B10 315/4885KCNQ2 2235/4885
US-20050154051-A1 Method for the preparation of escitalopram SLC6A4, TPH2, SLC6A3 LMNA 2498/4885HSD17B10 337/4885KCNQ2 778/4885
US-20200181128-A1 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, TPH1 LMNA 4834/4885HSD17B10 315/4885KCNQ2 2235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.